SRL
ITCI

Scientech Research LLC’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Scientech Research LLC’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-35,270
Closed -$2.42M – 890
2024
Q2 		$2.42M Buy
+35,270
New +$2.45M 0.5% 20

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Scientech Research LLC's ITCI Position: Q3 2024 in Review

Scientech Research LLC sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2024, closing a stake of 35,270 shares — an estimated $2.42M sold.

Scientech Research LLC first reported a position in ITCI in Q2 2024 and held it in 1 quarter. The position peaked at $2.42M in Q2 2024. 354 funds tracked by Wall St. Rank hold ITCI as of Q3 2024.

  • Scientech Research LLC reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2024 after selling out during the quarter.
  • Scientech Research LLC sold 35,270 Intra-Cellular Therapies Inc. shares in Q3 2024, an estimated $2.42M.
  • Scientech Research LLC first reported a position in Intra-Cellular Therapies Inc. in Q2 2024 and held it in 1 quarter.
  • Scientech Research LLC's Intra-Cellular Therapies Inc. position peaked at $2.42M in Q2 2024.
  • 354 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2024.

Based on Scientech Research LLC's 13F filing for Q3 2024, filed 14 Nov 2024.